{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:24:28Z","timestamp":1794349468448,"version":"4.9.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T00:00:00Z","timestamp":1762214400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004423","name":"World Health Organization","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004423","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000030","name":"Centers for Disease Control and Prevention","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000030","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eClinicalMedicine"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.eclinm.2025.103659","type":"journal-article","created":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T10:27:35Z","timestamp":1764757655000},"page":"103659","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020\u20132022: an, open-label, non-inferiority, randomised, controlled phase 2 trial"],"prefix":"10.1016","volume":"90","author":[{"given":"Edna","family":"Omar Viegas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4963-7962","authenticated-orcid":false,"given":"Emilia","family":"Fumane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-2805","authenticated-orcid":false,"given":"Kassia","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-6966-4465","authenticated-orcid":false,"given":"Mahira","family":"Amade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilesh","family":"Jani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"On\u00e9lia","family":"Guilche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5887-9174","authenticated-orcid":false,"given":"Catildo","family":"Cubai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo A.","family":"Mainou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3424-4030","authenticated-orcid":false,"given":"Rocio","family":"Lopez Cavestany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Visalakshi","family":"Jeyaseelan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.eclinm.2025.103659_bib5","doi-asserted-by":"crossref","first-page":"776","DOI":"10.15585\/mmwr.mm7123a3","article-title":"Notes from the field: initial outbreak response activity following wild poliovirus type 1 detection\u2013malawi, February 2022","volume":"71","author":"MoH Malawi","year":"2022","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eclinm.2025.103659_bib8","series-title":"Thirty-eighth meeting of the IHR emergency committee for polio","year":"2024"},{"key":"10.1016\/j.eclinm.2025.103659_bib10","series-title":"Global synchronisation and the switch","year":"2016"},{"issue":"25","key":"10.1016\/j.eclinm.2025.103659_bib11","first-page":"699","article-title":"Introduction of inactivated poliovirus vaccine and switch from trivalent to bivalent oral poliovirus vaccine\u2013worldwide, 2013-2016","volume":"64","year":"2015","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"10","key":"10.1016\/j.eclinm.2025.103659_bib12","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/infdis\/jiy739","article-title":"Inactivated poliovirus vaccine supply shortage: is there light at the end of the tunnel?","volume":"220","author":"Sutter","year":"2019","journal-title":"J Infect Dis"},{"issue":"suppl_1","key":"10.1016\/j.eclinm.2025.103659_bib13","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1093\/infdis\/jix185","article-title":"Lessons learned from managing the planning and implementation of inactivated polio vaccine introduction in support of the polio endgame","volume":"216","author":"Zipursky","year":"2017","journal-title":"J Infect Dis"},{"issue":"48","key":"10.1016\/j.eclinm.2025.103659_bib14","first-page":"561","volume":"91","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103659_bib15","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4103\/2224-3151.239418","article-title":"National introduction of fractional-dose inactivated polio vaccine in Sri Lanka following the global \"switch\"","volume":"7","author":"Gamage","year":"2018","journal-title":"WHO South East Asia J Public Health"},{"issue":"5","key":"10.1016\/j.eclinm.2025.103659_bib16","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2471\/BLT.18.218370","article-title":"Fractional-dose inactivated poliovirus vaccine, India","volume":"97","author":"Haldar","year":"2019","journal-title":"Bull World Health Organ"},{"issue":"suppl_1","key":"10.1016\/j.eclinm.2025.103659_bib17","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1093\/infdis\/jiw510","article-title":"Lessons learned from the introduction of inactivated poliovirus vaccine in Bangladesh","volume":"216","author":"Estivariz","year":"2017","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103659_bib18","article-title":"Achieving high immunogenicity against poliovirus with fractional doses of inactivated poliovirus vaccine in Ecuador-results from a cross-sectional serological survey","volume":"11","author":"Trueba","year":"2022","journal-title":"Lancet Reg Health Am"},{"issue":"98","key":"10.1016\/j.eclinm.2025.103659_bib19","first-page":"239","article-title":"March 2023: conclusions and recommendations","volume":"22","year":"2023","journal-title":"Wkly Epidemiol Rec"},{"issue":"3","key":"10.1016\/j.eclinm.2025.103659_bib20","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2471\/BLT.10.079426","article-title":"Intradermal delivery of vaccines: potential benefits and current challenges","volume":"89","author":"Hickling","year":"2011","journal-title":"Bull World Health Organ"},{"issue":"22","key":"10.1016\/j.eclinm.2025.103659_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2017.03.008","article-title":"Immunogenicity to poliovirus type 2 following two doses of fractional intradermal inactivated poliovirus vaccine: a novel dose sparing immunization schedule","volume":"35","author":"Anand","year":"2017","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.eclinm.2025.103659_bib22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/jpids\/piab091","article-title":"Immunogenicity of fractional dose inactivated poliovirus vaccine in India","volume":"11","author":"Ahmad","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"issue":"34","key":"10.1016\/j.eclinm.2025.103659_bib23","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.1016\/j.vaccine.2012.11.021","article-title":"Intradermal delivery for vaccine dose sparing: overview of current issues","volume":"31","author":"Zehrung","year":"2013","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.eclinm.2025.103659_bib24","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1093\/infdis\/jiu841","article-title":"Comparison of the immunogenicity of various booster doses of inactivated polio vaccine delivered intradermally versus intramuscularly to HIV-infected adults","volume":"211","author":"Troy","year":"2015","journal-title":"J Infect Dis"},{"issue":"36","key":"10.1016\/j.eclinm.2025.103659_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2013.05.104","article-title":"Intradermal fractional booster dose of inactivated poliomyelitis vaccine with a jet injector in healthy adults","volume":"31","author":"Soonawala","year":"2013","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.eclinm.2025.103659_bib26","first-page":"895","article-title":"Immunogenicity of intramuscular fractional dose of inactivated poliovirus vaccine","volume":"221","author":"Resik","year":"2020","journal-title":"J Infect Dis"},{"key":"10.1016\/j.eclinm.2025.103659_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4939-3292-4_8","article-title":"Standardized methods for detection of poliovirus antibodies","volume":"1387","author":"Weldon","year":"2016","journal-title":"Methods Mol Biol"},{"issue":"Suppl 1","key":"10.1016\/j.eclinm.2025.103659_bib28","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1093\/cid\/ciy649","article-title":"Impact of maternal antibody on the immunogenicity of inactivated polio vaccine in infants immunized with bivalent oral polio vaccine: implications for the polio eradication endgame","volume":"67","author":"Gaensbauer","year":"2018","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.eclinm.2025.103659_bib29","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/infdis\/jiac205","article-title":"One full or two fractional doses of inactivated poliovirus vaccine for Catch-up vaccination in older infants: a randomized clinical trial in Bangladesh","volume":"226","author":"Aziz","year":"2022","journal-title":"J Infect Dis"},{"issue":"33","key":"10.1016\/j.eclinm.2025.103659_bib30","doi-asserted-by":"crossref","first-page":"859","DOI":"10.15585\/mmwr.mm6533a5","article-title":"Fractional-dose inactivated poliovirus vaccine immunization campaign \u2014 telangana state, India","volume":"65","author":"Bahl","year":"2016","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"47","key":"10.1016\/j.eclinm.2025.103659_bib31","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.15585\/mmwr.mm6647a4","article-title":"Fractional-dose inactivated poliovirus vaccine campaign \u2014 sindh province, Pakistan, 2016","volume":"66","author":"Pervaiz","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"18","key":"10.1016\/j.eclinm.2025.103659_bib32","article-title":"Feasibility of conducting intradermal vaccination campaign with inactivated poliovirus vaccine using Tropis intradermal needle free injection system, Karachi, Pakistan","volume":"3","author":"Yousafzai MS","year":"2017","journal-title":"Heliyon"},{"issue":"47","key":"10.1016\/j.eclinm.2025.103659_bib33","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.15585\/mmwr.mm7247a3","article-title":"Notes from the field: house-To-house campaign administration of inactivated poliovirus vaccine \u2014 sokoto state, Nigeria, November 2022","volume":"72","author":"Biya","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.eclinm.2025.103659_bib34","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1038\/s41577-023-00941-2","article-title":"Immunological factors linked to geographical variation in vaccine responses","volume":"24","author":"Dorst","year":"2024","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"10.1016\/j.eclinm.2025.103659_bib35","doi-asserted-by":"crossref","first-page":"e1860","DOI":"10.1016\/S2214-109X(24)00340-1","article-title":"Schistosome and malaria exposure and urban-rural differences in vaccine responses in Uganda: a causal mediation analysis using data from three linked randomised controlled trials","volume":"12","author":"Natukunda","year":"2024","journal-title":"Lancet Glob Health"},{"issue":"99","key":"10.1016\/j.eclinm.2025.103659_bib36","first-page":"285","article-title":"March 2024: conclusions and recommendations","volume":"22","year":"2024","journal-title":"Wkly Epidemiol Rec"}],"container-title":["eClinicalMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589537025005930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T21:38:53Z","timestamp":1794346733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589537025005930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S2589537025005930"],"URL":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103659","relation":{},"ISSN":["2589-5370"],"issn-type":[{"value":"2589-5370","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intramuscular versus intradermal administration of fractional dose inactivated poliovirus vaccine in Mozambique, 2020\u20132022: an, open-label, non-inferiority, randomised, controlled phase 2 trial","name":"articletitle","label":"Article Title"},{"value":"eClinicalMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eclinm.2025.103659","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103659"}}